Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proscar: five-year experience

E Moore1, B Bracken, W Bremner

  • 1Merck Research Laboratories, Rahway, NJ 07065, USA.

European Urology
|January 1, 1995
PubMed
Summary

Long-term finasteride treatment for benign prostatic hyperplasia (BPH) effectively reduced prostate volume and improved urinary flow rates. This 5-year study demonstrated finasteride

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic reprogramming of CD4⁺ T cells by Zaprinast induces HIV-1 latency reversal ex vivo.

Retrovirology·2026
Same author

From fixing to connecting: parents' experiences supporting adult children with eating disorders.

Journal of eating disorders·2024
Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024
Same author

Graphene-Based Materials in Dental Applications: Antibacterial, Biocompatible, and Bone Regenerative Properties.

International journal of biomaterials·2023
Same author

Gastric outlet obstruction secondary to a wandering spleen: systematic review and surgical management of a case.

Annals of the Royal College of Surgeons of England·2023
Same author

Lean body weight local anaesthesia topicalisation charts for awake tracheal intubation.

Anaesthesia·2022

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition affecting aging men.
  • Symptomatic BPH significantly impacts quality of life.
  • 5 alpha-reductase inhibitors are a therapeutic option for BPH.

Purpose of the Study:

  • To assess the long-term safety and efficacy of finasteride in patients with symptomatic BPH.
  • To evaluate the effects of finasteride on prostate volume, urinary flow, and symptom scores over 5 years.

Main Methods:

  • A 5-year open-label extension study involving patients previously treated with finasteride.
  • Prostate volume measured by MRI, maximum urinary flow rate assessed noninvasively.
  • Patient-reported symptom scores evaluated using a standardized questionnaire.

Related Experiment Videos

Main Results:

  • Prostate volume reduced by 30% and dihydrotestosterone by 72% over 5 years.
  • Maximum urinary flow rate improved by approximately 1.5 ml/s.
  • Finasteride was well-tolerated, with approximately 10% reporting drug-related sexual adverse experiences, a rate that did not increase with treatment duration.

Conclusions:

  • Five-year finasteride therapy effectively inhibits BPH progression.
  • Finasteride demonstrates an excellent safety profile for long-term BPH management.
  • Finasteride represents a low-risk medical option for symptomatic BPH.